Clinical Trials Logo

Cystitis, Interstitial clinical trials

View clinical trials related to Cystitis, Interstitial.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06212661 Enrolling by invitation - Migraine Clinical Trials

Migraine Medication Effects on Urinary Symptoms

Start date: March 2024
Phase:
Study type: Observational

A prospective observational cohort trial to study the effects of CGRP inhibitors (CGRPi) on lower urinary tract symptoms (LUTS) and bladder/pelvic pain. Candidates for either CGRPi or an alternative therapy for refractory migraines (OnabotulinumtoxinA (BoNTA) extracranial muscle injections) with baseline LUTS will be recruited. The investigators will assess LUTS and pelvic pain using validated symptom and quality-of-life questionnaires, pretreatment and at 3 months post-treatment follow-up, comparing change in symptoms based on treatment received.

NCT ID: NCT05456308 Enrolling by invitation - Clinical trials for Interstitial Cystitis

What is the Optimal Technique for Hydrodistention?

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

This research study is being done to learn what is the best way to perform hydrodistention. Eligible participants will be enrolled and have follow-up for three months after surgery. The study team hypothesizes that changes in hydrodistention technique, including pressure, number of distention, and duration of distention, leads to no or minimal changes in symptom improvement for patients with Interstitial cystitis/bladder pain syndrome (IC/BPS).

NCT ID: NCT01301365 Enrolling by invitation - Clinical trials for Interstitial Cystitis

Autonomic Response During Cystodistension in Patients Suspected of Having Interstitial Cystitis

Start date: November 2010
Phase: N/A
Study type: Observational

The aim of this study is to check whether patients with cystoscopic findings supporting the diagnosis of Interstitial Cystitis (IC) have a higher autonomic response (change in blood pressure / pulse)than patients without cystoscopic findings.

NCT ID: NCT01157507 Enrolling by invitation - Clinical trials for Painful Bladder Syndrome (PBS)

Botulinum A Toxin in the Treatment of Patients With Painful Bladder Syndrome

Start date: January 2010
Phase: Phase 4
Study type: Interventional

Previous clinical observations showed that Botulinum A toxin (BoNT/A) has also an antinociceptive effect and can control the neuropathic pain. In the urologic field, recent in in vitro and in in vivo studies demonstrated that the neurotoxin is able to inhibit the release of several neurotransmitters from the bladder afferent fibers and urothelium. These neurotrasmitters as SP, CGRP, ATP, NGF and Prostaglandins are involved in neurogenic inflammation. Thus, it is reasonable to hypothesize that patients with affected by painful bladder syndrome (PBS) could benefit from BoNT/A intravesically administered. The aim of the study is to investigate the clinical and urodynamic effects of an intravesical treatment with BoNT/A in patients affected by PBS associated with increased urinary frequency, who are refractory to conventional treatments. This treatment will be compared to bladder over distention, which is considered a conventional therapy.